Elevation Oncology (ELEV)
(Delayed Data from NSDQ)
$0.78 USD
+0.02 (2.34%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $0.77 -0.01 (-1.03%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Price, Consensus and EPS Surprise
ELEV 0.78 +0.02(2.34%)
Will ELEV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ELEV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ELEV
Are Medical Stocks Lagging Elevation Oncology (ELEV) This Year?
ELEV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ELEV
Merus: Great European Oncology Developer, But Properly Valued
Undercovered Dozen: Elevation Oncology, Ivanhoe Mines, Union Pacific, Golub Capital +
Buy Rating Affirmed for Elevation Oncology Amid Promising EO-3021 Phase 1 Results and Strategic Development Approach
Elevation Oncology’s Promising Prospects and Buy Rating Endorsed by Analyst Marc Frahm
Crude Oil Moves Higher; Yum! Brands Posts Upbeat Earnings